Royalty Pharma to Pay Potential $500M for Royalties on Ferring’s Gene Therapy

Swiss company Ferring Pharmaceuticals got a major boost from the world’s largest buyer of biopharma royalties with Thursday's announcement that Royalty Pharma is paying $300 million upfront—and offering $200 million in manufacturing-milestone payments—for access to Ferring’s Adstiladrin, an FDA-approved gene therapy treatment for bladder cancer.